LEXARIA BIOSCIENCE CORP. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
LEXARIA BIOSCIENCE CORP. (LEXX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $1.94 million for the 12-month period ending 2025-08-31, per its 10-K filed 2025-11-28.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2025-11-28
- LEXARIA BIOSCIENCE CORP. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2025 was $1.94M, a 44.15% increase from fiscal 2024.
- LEXARIA BIOSCIENCE CORP. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2024 was $1.35M, a 263.05% increase from fiscal 2023.
- LEXARIA BIOSCIENCE CORP. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2023 was $371.33K.
- LEXARIA BIOSCIENCE CORP. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2022 was $0.00.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month |
|---|---|
| 2025-08-31 | $1.94M 10-K · filed 2025-11-28 |
| 2024-08-31 | $1.35M 10-K · filed 2025-11-28 |
| 2023-08-31 | $371.33K 10-K · filed 2024-11-26 |
| 2022-08-31 | $0.00 10-K · filed 2023-11-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |